Therapy News and Research

RSS

Cedars-Sinai educational conference to focus on patient empowerment

Brain tumor patients, families and caregivers are invited to an educational conference that will focus on patient empowerment June 23 at Cedars-Sinai Medical Center.

23 Jun 2012

EMA CHMP adopts positive opinion for Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler (glycopyrronium/NVA237) 44 mcg delivered dose (50 mcg glycopyrronium per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

23 Jun 2012

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

AMAG Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

23 Jun 2012

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Apply the ointment, light on, light off - that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy.

23 Jun 2012

‘Take home’ methadone maintenance therapy has added benefits

Patients who are given “take home” methadone maintenance treatment for opioid dependence are less likely to be admitted to hospital than those who do not, a study shows.

22 Jun 2012

ATS task force recommends annual lung cancer screening using LDCT

A lung screening and surveillance task force, established by the American Association for Thoracic Surgery (AATS) and led by medical professionals from Brigham and Women's Hospital (BWH), is strongly recommending new guidelines for lung cancer screening. The guidelines were published this week in the online edition of the Journal of Thoracic and Cardiovascular Surgery (JTCVS).

22 Jun 2012

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).

22 Jun 2012

Wraparound knee brace for osteoarthritis patients

Breg, Inc., a premier provider of sports medicine products and services, has introduced five new products, including a first-of-its-kind wraparound knee brace for osteoarthritis (OA) patients. New products also include two ankle braces designed to help prevent ankle injury, a cold therapy system with longer ice time, and an upgrade to Breg's inventory management system created specifically for the orthopedic office.

22 Jun 2012

Abbott challenges copies of its biologic drugs

If the challenge succeeds, less-expensive versions of complex biologic drugs couldn't go on sale in the U.S. for years, and consumers may never have access to facsimiles of existing treatments such as Abbott's rheumatoid arthritis therapy Humira.

22 Jun 2012

Novel small-molecule-inhibiting drug stops spread of breast cancer cells

Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites.

22 Jun 2012

First Edition: June 22, 2012

Reporting for Kaiser Health News, Roni Caryn Rabin writes: "They say everything is bigger in Texas, and the problem of the uninsured is no exception. The Houston metropolitan area has one of the highest rates of uninsured people in America, and a health safety net imploding under the demands of too many people and too few resources.

22 Jun 2012

Evolutionary principles of natural selection may be applied to successfully manage cancer

According to researchers at Moffitt Cancer Center, cancer is subject to the evolutionary processes laid out by Charles Darwin in his concept of natural selection. Natural selection was the process identified by Darwin by which nature selects certain physical attributes, or phenotypes, to pass on to offspring to better "fit" the organism to the environment.

22 Jun 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

22 Jun 2012

DBS can improve muscle symptoms in patients with Parkinson's

Patients with Parkinson's disease who undergo deep brain stimulation (DBS)—a treatment in which a pacemaker-like device sends pulses to electrodes implanted in the brain—can expect stable improvement in muscle symptoms for at least three years, according to a Department of Veterans Affairs study appearing in the most recent issue of the journal Neurology.

22 Jun 2012

Lead 8A analog can treat osteosarcoma in children

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

22 Jun 2012

Short-term antiarrhythmic drug treatment postcardioversion could be effective

Short-term antiarrhythmic drug treatment after cardioversion is less effective than long-term treatment, but prevents most recurrences of atrial fibrillation, a study in The Lancet shows.

21 Jun 2012

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according to research by Mount Sinai School of Medicine.

21 Jun 2012

Gracilis muscle flap an effective treatment for facial paralysis in patients with NF2

A surgical technique using a muscle flap from the thigh restores facial motion—and the ability to smile—in patients with facial nerve paralysis resulting from neurofibromatosis type 2 (NF2), reports a study in this month's special "Operative Neurosurgery" supplement to Neurosurgery, official journal of the Congress of Neurological Surgeons.

21 Jun 2012

FOXO3a transcription factor actually promotes growth of anaplastic thyroid cancer

A molecule widely believed to fight many forms of cancer actually helps deadly thyroid tumors grow, and cancer therapies now being tested in humans might boost the activity of this newly revealed bad guy, researchers at Mayo Clinic in Florida say.

21 Jun 2012